KEI and UACT comments on the prospective grant of exclusive licenses to Sinotau and MTTI

On August 27, 2018, Knowledge Ecology International (KEI) and the Union for Affordable Cancer Treatment (UACT) filed comments to the NIH regarding the prospective grant of two separate exclusive licenses to Sinotau Pharmaceutical Group and Molecular Targeting Technologies, Inc. (MTTI),… Continue Reading

INB 9 – Oral statement by Knowledge Ecology International

On Monday, 18 March 2024, Knowledge Ecology International (KEI) delivered the following oral statement (in person) at the 9th meeting of the World Health Organization’s (WHO) Intergovernmental Negotiating Body (INB). With respect to Article 11.2, the current references to “to… Continue Reading

Request for Amendment to add Risdiplam for Spinal Muscular Atrophy (SMA) to Schedule 1 of the Canadian Patent Act

On March 1st, Knowledge Ecology International sent a letter to The Hon. Mark Holland, Ministry of Health, and The Hon. François-Philippe Champagne, Minister of Innovation, Science, and Industry, urging the prompt consideration of adding risdiplam, a drug to treat spinal… Continue Reading

KEI Comments to the NIH License on Gene Therapy to Marble Therapeutics

Today Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: Vaccine Augmented Adoptive Cell Therapy for the Treatment of Cancer” (89 FR 8438). The wordwide, exclusive license… Continue Reading

KEI Comment to NIST on the Bayh-Dole Letter to the Washington Post and the Legislative History of the Act

KEI submitted comments to the National Institute of Standards and Technology (NIST) issued a Request for Information regarding the “Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights” (88 FR 85593) regarding the 2002 Bob Dole and Birch… Continue Reading

KEI Comment to NIST on “Available to the Public on Reasonable Terms”

On February 6, 2024, KEI submitted comments to the National Institute of Standards and Technology (NIST) regarding the Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights (88 FR 85593). This set of comments outlined that the draft… Continue Reading

NIST Draft Guidance on Exercising March-in Rights

The National Institute of Standards and Technology (NIST) issued a Request for Information on December 8, 2023 regarding the “Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights” (88 FR 85593). The request follows a nearly year-long interagency… Continue Reading

KEI Comment to NIST on Bayh-Dole Rights and Cases of Mixed Patent Landscapes

KEI submitted comments to the National Institute of Standards and Technology (NIST) in response to the Request for Information regarding the “Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights” (88 FR 85593) concerning Bayh-Dole rights and the… Continue Reading

KEI Comment to NIST on Transparency of March-in Proceedings

On December 8, 2023, the National Institute of Standards and Technology (NIST) issued a Request for Information regarding the “Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights” (88 FR 85593). Today KEI submitted comments to NIST regarding… Continue Reading